The board of directors of SSY Group Limited announced that the Group's Isoprenaline hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market, being the second of such approval in the PRC.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.61 HKD | -2.54% | -4.75% | -6.68% |
May. 22 | SSY Group’s Bronchitis Drug Gets Registration Approval in China | MT |
May. 21 | SSY Group Gets Production and Registration Approval for Parkinson’s Disease Drug in China | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.68% | 1.8B | |
+38.69% | 728B | |
+33.08% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+15.80% | 244B | |
+7.81% | 207B | |
-5.36% | 205B | |
+6.42% | 164B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development